Krystal Biotech, Inc. (NASDAQ:KRYS) Short Interest Update

Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report) was the target of a significant drop in short interest during the month of February. As of February 28th, there was short interest totalling 2,760,000 shares, a drop of 13.5% from the February 13th total of 3,190,000 shares. Currently, 11.2% of the company's shares are sold short. Based on an average trading volume of 278,600 shares, the short-interest ratio is presently 9.9 days.

Wall Street Analysts Forecast Growth

KRYS has been the subject of a number of recent research reports. Citigroup boosted their price objective on shares of Krystal Biotech from $206.00 to $215.00 and gave the company a "neutral" rating in a report on Thursday, February 20th. Chardan Capital lifted their target price on Krystal Biotech from $212.00 to $218.00 and gave the company a "buy" rating in a research report on Thursday, February 20th. HC Wainwright reiterated a "buy" rating and issued a $221.00 price target on shares of Krystal Biotech in a research note on Friday, February 28th. Jefferies Financial Group initiated coverage on shares of Krystal Biotech in a research report on Wednesday, March 5th. They issued a "buy" rating and a $245.00 price target for the company. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $215.00 target price on shares of Krystal Biotech in a report on Thursday, February 20th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Krystal Biotech presently has a consensus rating of "Buy" and a consensus price target of $220.00.

Remove Ads

Insider Activity at Krystal Biotech

In other Krystal Biotech news, CAO Kathryn Romano sold 750 shares of the firm's stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $175.22, for a total value of $131,415.00. Following the completion of the transaction, the chief accounting officer now directly owns 12,604 shares in the company, valued at $2,208,472.88. This trade represents a 5.62 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the completion of the transaction, the insider now directly owns 1,463,711 shares of the company's stock, valued at approximately $260,233,178.69. This trade represents a 1.68 % decrease in their position. The disclosure for this sale can be found here. 14.10% of the stock is owned by company insiders.

Institutional Investors Weigh In On Krystal Biotech

Hedge funds have recently made changes to their positions in the company. Oppenheimer Asset Management Inc. purchased a new position in Krystal Biotech in the 3rd quarter worth approximately $235,000. KBC Group NV increased its stake in shares of Krystal Biotech by 25.9% in the 3rd quarter. KBC Group NV now owns 642 shares of the company's stock worth $117,000 after purchasing an additional 132 shares in the last quarter. Swiss National Bank increased its position in Krystal Biotech by 8.0% in the third quarter. Swiss National Bank now owns 39,100 shares of the company's stock worth $7,117,000 after buying an additional 2,900 shares in the last quarter. Quest Partners LLC raised its stake in Krystal Biotech by 264.1% during the 3rd quarter. Quest Partners LLC now owns 1,398 shares of the company's stock worth $254,000 after acquiring an additional 1,014 shares during the period. Finally, Segall Bryant & Hamill LLC raised its position in shares of Krystal Biotech by 352.4% during the 3rd quarter. Segall Bryant & Hamill LLC now owns 157,144 shares of the company's stock valued at $28,605,000 after purchasing an additional 122,407 shares during the period. 86.29% of the stock is currently owned by institutional investors.

Krystal Biotech Trading Down 0.8 %

Shares of Krystal Biotech stock traded down $1.46 on Friday, hitting $187.15. 328,246 shares of the company traded hands, compared to its average volume of 284,188. The firm's 50-day simple moving average is $166.67 and its 200 day simple moving average is $173.56. Krystal Biotech has a 12-month low of $141.72 and a 12-month high of $219.34. The company has a market cap of $5.39 billion, a P/E ratio of 62.59 and a beta of 0.87.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its earnings results on Monday, February 24th. The company reported $1.52 EPS for the quarter, topping the consensus estimate of $1.29 by $0.23. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The company had revenue of $91.10 million for the quarter, compared to the consensus estimate of $91.35 million. During the same period in the previous year, the firm earned $0.30 earnings per share. The firm's revenue for the quarter was up 116.4% on a year-over-year basis. Analysts predict that Krystal Biotech will post 6.14 earnings per share for the current year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).